PomDoctor Receives Nasdaq Deficiency Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Should l Buy POM?
PomDoctor announced that it has received a written notification from the staff of Nasdaq dated January 29, indicating that for the last 33 consecutive business days, the closing bid price of the company's American depositary shares was below the minimum bid price of $1.00 per share requirement set forth in Nasdaq Listing Rule 5450. The Deficiency Letter has no current effect on the listing or trading of the company's ADSs on Nasdaq. Pursuant to Nasdaq Listing Rule 5810, the company is provided with a compliance period of 180 calendar days, or until July 28, to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the compliance period, the closing bid price of the company's ADSs is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will provide the company a written confirmation of compliance and the matter will be closed. In the event the company does not regain compliance by July 28, subject to the determination by the staff of Nasdaq, the company may be eligible for additional time. The deficiency letter will have no effect on the company's business operations, and the company will take all reasonable measures to regain compliance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy POM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on POM
About POM
PomDoctor Ltd is a holding company principally engaged in operating a online medical services platform for chronic diseases. The Company operates its businesses through two segments. The Internet Hospital segment mainly engaged in providing online follow-up consultations and online prescription renewal service to customers and also sells prescription to customers through the website and apps. The Pharmaceutical Supply Chain segment mainly engaged in pharmacy retail sales and wholesale. The Company mainly operates its businesses in the domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Lawsuit Filed Against PomDoctor Ltd.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of PomDoctor Ltd. (NASDAQ: POM) securities from October 9 to December 11, 2025, indicating potential investor losses due to misleading information.
- Compensation Structure: Investors joining the lawsuit may receive compensation without any upfront fees, highlighting the accessibility of legal services and the protection of investor rights.
- Allegations of False Statements: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, failing to disclose a fraudulent stock promotion scheme involving social media, which resulted in investor losses.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in protecting investor interests.
See More
Class Action Lawsuit Announced for PomDoctor Securities
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of PomDoctor Ltd. (NASDAQ:POM) investors who purchased securities between October 9 and December 11, 2025, indicating significant legal risks that could impact the company's stock performance.
- Compensation Structure: Investors participating in the lawsuit may receive compensation without any out-of-pocket costs, a contingency fee arrangement that could attract more affected investors and enhance the lawsuit's overall impact.
- Allegations of Misrepresentation: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, failing to disclose a fraudulent stock promotion scheme involving social media, which may have led to investor losses and heightened concerns about the company's transparency.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, which may bolster investor confidence in the lawsuit's potential outcomes.
See More
Pomdoctor Investors Encouraged to Discuss Legal Options
- Legal Claim Investigation: Faruq & Faruqi LLP is investigating potential claims against Pomdoctor, specifically targeting investors who purchased securities between October 9, 2025, and December 11, 2025, to safeguard their legal rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, ensuring timely action is taken.
- Class Action Deadline: Investors in Pomdoctor should note that the deadline to seek the role of lead plaintiff in the federal securities class action is April 6, 2026, emphasizing the importance of prompt action to protect their interests.
- Company Background: Pomdoctor Limited (NASDAQ:POM) is facing legal challenges, and the investigation by Faruq & Faruqi LLP may impact the company's reputation and shareholder returns, prompting investors to closely monitor developments.
See More
PomDoctor Faces Class Action Lawsuit Over Investor Misleading Claims
- Class Action Initiated: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased PomDoctor (NASDAQ: POM) securities between October 9, 2025, and December 11, 2025, alleging that the company misled investors regarding its operations, potentially leading to significant investor losses.
- False Promotion Allegations: The lawsuit claims that PomDoctor was involved in a fraudulent stock promotion scheme utilizing social media misinformation and impersonation of financial professionals, with insiders using offshore accounts to coordinate share dumping during a price inflation campaign, severely impacting investor decisions.
- Disclosure Failures: PomDoctor's public statements and risk disclosures omitted any mention of false rumors and artificial trading activities, resulting in investors' positive perceptions of the company's business and prospects lacking a reasonable basis, further exacerbating investor losses.
- Next Steps in Litigation: Investors wishing to serve as lead plaintiffs in the class action must file their motions with the court by April 7, 2026, while shareholders who choose not to participate can remain absent class members and still retain eligibility for recovery.
See More
PomDoctor Faces Class Action Lawsuit for Securities Fraud
- Class Action Filed: Scott+Scott Attorneys at Law LLP has initiated a class action lawsuit against PomDoctor Ltd. in the U.S. District Court for the Southern District of New York, alleging that the company misled investors through false statements and omissions during the period from October 9 to December 11, 2025, with case number 1:26-cv-01013.
- Stock Collapse Allegations: The lawsuit claims that PomDoctor's stock experienced a sudden collapse in December 2025 due to an illicit social media promotion scheme that artificially inflated its price, resulting in significant losses for investors and characterizing the situation as a
See More
POMDOCTOR Faces Shareholder Class Action Lawsuit
- False Promotion Allegations: POMDOCTOR LIMITED is accused of being involved in a fraudulent stock promotion scheme that utilized social media misinformation, leading to significant investor losses and severely damaging the company's reputation and stock price.
- Insider Trading Suspicions: The lawsuit claims that insiders or affiliates used offshore accounts to facilitate coordinated share dumping, exacerbating the artificial inflation of stock prices and potentially inviting regulatory scrutiny and penalties.
- Inadequate Disclosure: POMDOCTOR's public statements failed to mention the false rumors and artificial trading activities, which could undermine investor confidence in the company's future and negatively impact its market performance.
- Legal Implications: Investors who purchased POMDOCTOR shares between October 9, 2025, and December 11, 2025, and experienced significant losses are urged to apply to be lead plaintiffs by April 6, 2026, highlighting the urgency of the legal proceedings.
See More
Class Action Lawsuit Filed Against PomDoctor Ltd.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of PomDoctor Ltd. (NASDAQ: POM) securities from October 9 to December 11, 2025, indicating potential investor losses due to misleading information.
- Compensation Structure: Investors joining the lawsuit may receive compensation without any upfront fees, highlighting the accessibility of legal services and the protection of investor rights.
- Allegations of False Statements: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, failing to disclose a fraudulent stock promotion scheme involving social media, which resulted in investor losses.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in protecting investor interests.
See More
Class Action Lawsuit Announced for PomDoctor Securities
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of PomDoctor Ltd. (NASDAQ:POM) investors who purchased securities between October 9 and December 11, 2025, indicating significant legal risks that could impact the company's stock performance.
- Compensation Structure: Investors participating in the lawsuit may receive compensation without any out-of-pocket costs, a contingency fee arrangement that could attract more affected investors and enhance the lawsuit's overall impact.
- Allegations of Misrepresentation: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, failing to disclose a fraudulent stock promotion scheme involving social media, which may have led to investor losses and heightened concerns about the company's transparency.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, which may bolster investor confidence in the lawsuit's potential outcomes.
See More
Pomdoctor Investors Encouraged to Discuss Legal Options
- Legal Claim Investigation: Faruq & Faruqi LLP is investigating potential claims against Pomdoctor, specifically targeting investors who purchased securities between October 9, 2025, and December 11, 2025, to safeguard their legal rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, ensuring timely action is taken.
- Class Action Deadline: Investors in Pomdoctor should note that the deadline to seek the role of lead plaintiff in the federal securities class action is April 6, 2026, emphasizing the importance of prompt action to protect their interests.
- Company Background: Pomdoctor Limited (NASDAQ:POM) is facing legal challenges, and the investigation by Faruq & Faruqi LLP may impact the company's reputation and shareholder returns, prompting investors to closely monitor developments.
See More
PomDoctor Faces Class Action Lawsuit Over Investor Misleading Claims
- Class Action Initiated: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased PomDoctor (NASDAQ: POM) securities between October 9, 2025, and December 11, 2025, alleging that the company misled investors regarding its operations, potentially leading to significant investor losses.
- False Promotion Allegations: The lawsuit claims that PomDoctor was involved in a fraudulent stock promotion scheme utilizing social media misinformation and impersonation of financial professionals, with insiders using offshore accounts to coordinate share dumping during a price inflation campaign, severely impacting investor decisions.
- Disclosure Failures: PomDoctor's public statements and risk disclosures omitted any mention of false rumors and artificial trading activities, resulting in investors' positive perceptions of the company's business and prospects lacking a reasonable basis, further exacerbating investor losses.
- Next Steps in Litigation: Investors wishing to serve as lead plaintiffs in the class action must file their motions with the court by April 7, 2026, while shareholders who choose not to participate can remain absent class members and still retain eligibility for recovery.
See More
PomDoctor Faces Class Action Lawsuit for Securities Fraud
- Class Action Filed: Scott+Scott Attorneys at Law LLP has initiated a class action lawsuit against PomDoctor Ltd. in the U.S. District Court for the Southern District of New York, alleging that the company misled investors through false statements and omissions during the period from October 9 to December 11, 2025, with case number 1:26-cv-01013.
- Stock Collapse Allegations: The lawsuit claims that PomDoctor's stock experienced a sudden collapse in December 2025 due to an illicit social media promotion scheme that artificially inflated its price, resulting in significant losses for investors and characterizing the situation as a
See More
POMDOCTOR Faces Shareholder Class Action Lawsuit
- False Promotion Allegations: POMDOCTOR LIMITED is accused of being involved in a fraudulent stock promotion scheme that utilized social media misinformation, leading to significant investor losses and severely damaging the company's reputation and stock price.
- Insider Trading Suspicions: The lawsuit claims that insiders or affiliates used offshore accounts to facilitate coordinated share dumping, exacerbating the artificial inflation of stock prices and potentially inviting regulatory scrutiny and penalties.
- Inadequate Disclosure: POMDOCTOR's public statements failed to mention the false rumors and artificial trading activities, which could undermine investor confidence in the company's future and negatively impact its market performance.
- Legal Implications: Investors who purchased POMDOCTOR shares between October 9, 2025, and December 11, 2025, and experienced significant losses are urged to apply to be lead plaintiffs by April 6, 2026, highlighting the urgency of the legal proceedings.
See More
